erythropoiesis

3-(3,4-Dimethoxyphenyl)propanoic acid (3,4-Dimethoxyhydrocinnamic acid) is an orally active short-chain fatty acid (SCFAs) that promotes γ-globin gene expression and erythropoiesis in vivo, making it useful in treating beta hemoglobinopathies and other anemias.

Roxadustat-d5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg kg. Roxadustat reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5 6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......

Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.

Epoetin zeta, a derivative of the endogenous protein erythropoietin, functions as an erythropoiesis-stimulating agent. It is utilized to investigate symptomatic anemia associated with renal disorders, referred to as symptomatic renal anemia [1].

Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia.

Mitapivat (PKR-IN-1), also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.

Epoetin beta (rhEPO), a recombinant erythropoietin, is crucial for sustaining erythropoiesis and is utilized in anemia research [1].